Introduction

NRG HN002 [1] is a randomized phase II trial for patients with good-risk human papilloma virus (HPV)-associated oropharyngeal cancer (OPC). The trial will evaluate two new treatment options, one consisting of chemoradiotherapy and one of radiotherapy alone. The prescription dose is 60 Gy (2.0 Gy/fraction) over six weeks for arm 1 and over five weeks for arm 2. All patients will be managed with intensity modulated radiation therapy (IMRT) delivered with megavoltage photons. The goal of the trial is to evaluate whether these two modestly less-intensive therapies result in the same excellent outcomes and low treatment-associated toxicity observed in the RTOG 0129 [2] and RTOG 0522 [3] trials of oropharyngeal cancer. Further details on the NRG HN002 clinical trial can be found elsewhere [1].

The compliance criteria of clinical trials are often used as constraints for treatment planning and are always used for plan scoring upon final review [4]. Upon review at the Imaging and Radiation Oncology Core (IROC) RT QA center, treatment plans of patients enrolled in NRG-Oncology clinical trials are given scores of 1, 2 or 3. A treatment plan is given a score of 1 if it exactly meets the criteria; given a score of 2 if it falls within the variation acceptable range, and given a score of 3 and rejected if it violates the variation acceptable range. The method used for designing compliance criteria should optimally examine a large number of treatment plans that are considered to be the result of significant effort on the part of experienced treatment planners [4]. Such a process should take place prior to the activation of the clinical trial. However, in many cases, new clinical trials use dosimetric criteria and constraints of similar and previous trials and this may lead to repeated amendments of the newly developed trials when many participating institutions cannot meet the dosimetric constraints. Such repeated amendments are undesirable and may lead to confusion, especially in multi-institutional clinical trials. RTOG 1005, for example suffered from high failure rates in rapid review cases [5], as 35% of the rapid review plans failed to meet the compliance criteria of the protocol (either contouring or dosimetric criteria). Among these plans, 12% of the plans failed to meet the dosimetric criteria and the protocol was amended.
to relax the dosimetric criteria for the contralateral breast. NRG-Oncology, as a part of the quality assurance of its clinical trials, started to pro-actively test the dosimetric compliance criteria of any clinical trial and establish its feasibility prior to activation. As such, unnecessary future amendments, which may lead to confusion and also high failure rates during the RTQA process, can be easily avoided. Such a step represents an important improvement in the launch of a new clinical trial. In a previous study, the dosimetric compliance criteria of the RTOG 1308 clinical trial was investigated during the design stage of the trial [4]. The investigation study analyzed 26 pairs (each pair consisted of IMRT and proton passive scattered therapy (PSPT) plan) of treatment plans submitted by two major institutions. The plans were developed using institutional protocols that have similar guidelines to RTOG 1308 and the doses were scaled to the prescription dose of RTOG 1308. The study [4] helped in establishing feasible dosimetric criteria for RTOG 1308. This paper reports on assessing the dosimetric compliance criteria of clinical trials (applied to NRG HN002 trial) using a different approach. Here, DICOM CT and structures data of five bench mark cases were sent to different academic institutions and different treatment planning systems (Eclipse and Pinnacle) and delivery techniques (IMRT and VMAT) were used as a part of the trial planning process.

Methods and Materials

Dosimetric Compliance Criteria of NRG-HN002

Tables 1 & 2 lists the required dosimetric compliance criteria and the recommended dose acceptance criteria for some normal structures, respectively. The recommended dose criteria are used for planning guidance but not for plan evaluation. **Table 1: Dosimetric compliance criteria of NRG HN002 clinical Trial.**

| Name of structure | Dosimetric parameters | Per Protocol Dose (Gy) | Variation Acceptable |
|-------------------|-----------------------|------------------------|----------------------|
| PTV_6000          | D95%∗(Gy) ≤ 55.8      | 60                     | >60 and ≤ 63         |
|                   | D99%(Gy) ≤ 66         | ≥ 5.8                  | ≥ 54                 |
| CTV_6000          | V60 Gy (%) ≥ 99 %     | 95 to 99 %             |
| PTV_5400          | D95%∗(Gy) ≤ 50.2      | ≥ 54                   | ≥ 51.3               |
|                   | D99%(Gy) ≤ 66         | ≥ 50                   | ≥ 48                 |
| CTV_5400          | V54 Gy (%) ≥ 99 %     | 95 to 99 %             |
| PTV_4800          | D95%∗(Gy) ≤ 48        | ≥ 48                   | ≥ 44                 |
|                   | D99%(Gy) ≤ 44.6       | ≥ 48                   | ≥ 43.2               |
|                   | Dmav∗(Gy) ≤ 55.2      | ≤ 55.2                 | ≤ 57.6               |
| CTV_4800          | V48 Gy (%) ≥ 99 %     | 95 to 99 %             |
| SpinalCord_05     | Dmav∗(Gy) ≤ 48        | ≤ 48                   | ≤ 50                 |
| Spinal Cord       | Dmav∗(Gy) ≤ 45        | ≤ 50                   | ≤ 52                 |
| BrainStem_03      | Dmav∗(Gy) ≤ 50        | ≥ 50                   | ≥ 52                 |

* D95%∗(Gy) = dose to 95% of volume.
** Dmax = maximum dose to 0.03 cc of the volume.

**Table 2: Recommended dose acceptance criteria for other normal tissue, but not to be used for plan score.**

| Structure                      | Recommended dose acceptance criteria |
|-------------------------------|-------------------------------------|
| Parotid                       | Mean dose to one parotid ≤ 26 Gy    |
| Larynx                        | Mean dose ≤ 35 Gy                   |
| Pharynx                       | Mean dose ≤ 40 Gy                   |
| Submandible_R or Submandible_L | Mean Dose ≤ 39 Gy                   |
| Oral Cavity (Excludin PTV’s)   | Mean dose ≤ 32 Gy                   |
| Esophagus_Up                  | Mean dose ≤ 30 Gy                   |
| NonPTV                        | D1cc < 63 Gy                        |
| Mandible                      | D0.03cc < 63 Gy                     |

Treatment planning instructions and priorities

Table 3 summarizes the treatment planning instructions and priorities for target volumes and organs at risks.

Patient population and target definitions

Five bench mark patients, who were treated on a previous clinical trial of HPV-associated oropharyngeal cancer patients, RTOG 1016 and who met the more selective inclusion criteria for NRG HN002, were identified for this study. There was diversity among the cases with respect to the primary site within the oropharynx (tonsil or base of tongue), primary tumor stage (T stage), and nodal stage (N stage). The contours of the target volumes and organ at risk were redrawn according to the guidelines of NRG HN002. Figure 1 gives examples of axial views of two CT images included in this study and showing planning target volume (PTV) and organs at risk (OARs).

Treatment planning systems and delivery techniques

Two treatment planning systems were used to plan the five cases included in this study. These systems were Varian Eclipse version 11.0.30 (Varian Medical Systems, Palo Alto, CA) and

Citation: Giaddui T, Yu J, Doemer A, Matuszak M, Nunez F, et al. (2016) A feasibility Study of the Dosimetric Compliance Criteria of the NRG-HN002 Head and Neck Clinical Trial Across Different Radiotherapy Treatment Planning Systems and Delivery Techniques: A Model for Optimizing Initial Trial Launch. J Cancer Prev Curr Res 5(5): 00179. DOI: 10.15406/jcpcr.2016.05.00179
Philips Pinnacle version 9.10 (Philips Health Care, Fitchburg, WI). Plans were developed using either Intensity Modulated Radiation Therapy (IMRT) with nine beams at 40 degrees of separation from the anteroposterior axis and Volumetric Modulated Arc Therapy (VMAT) with two full arcs.

Table 3: Treatment planning instructions and priorities.

| Planning Target Volumes (PTVs) | PTVs are defined as either a 3 mm or 5 mm expansion of the related CTV in all planes |
|--------------------------------|---------------------------------------------------------------------------------|
| **PTVs edits:** | 1. When a PTV overlaps a critical OAR (spinal cord and/or brain stem) and its associated PRV, the PTV is modified to exclude the PRV, so that the dose delivered to the PRV remains within constraints.  
2. The PTV is constrained 5 mm within the external contour to spare the skin.  
3. For situations in which gross disease is external to the external contour (disease at or through the skin surface), the use of 5 mm tissue equivalent material (bolus) is required and no PTV constraint should be used underneath the bolus. |
| **Prioritization for IMRT Planning** | 1. Spinal cord and brain stem constraints.  
2. Coverage and homogeneity objectives for PTVs (PTV_6000, PTV_5400, PTV_4800 and PTV_4400).  
3. a. Parotid gland contralateral to tumor site.  
b. Larynx.  
4. a. Pharynx.  
b. Contralateral submandibular.  
5. a. Oral cavity.  
b. Lips.  
c. Esophagus.  
6. a. Parotid gland ipsilateral to tumor site.  
b. Mandible.  
7. Unspecified tissues outside the target. |

Plans in Pinnacle were developed using Pinnacle Auto-Planning. Pinnacle Auto-Planning is a software module available starting in version 9.10 that simplifies the planning process through the use of templates and automatic optimization tuning methods. It automatically mimics actions taken by an experienced dosimetrist to create an IMRT or VMAT plan. These actions include, but are not limited to, creating rings, managing structure overlaps between PTVs and OARs and controlling dose in hot and cold spots. The prioritized clinical goals defined in the template are translated into optimization objectives. The software is designed to continually optimize sparing of OARs, even beyond the clinical goals which were input by the planner, if possible, all while maintaining the user-specified dose uniformity in the PTV. Extra control regions of interest (ROIs) and objectives are added if necessary to automatically control dose uniformity to the target(s) and enforce the high priority goals of maximum dose [6].

**Data Analysis**

Dose volume histograms (DVHs) for all plans were compared using MIM Software, Inc. [7], which was only used to display, compare and analyze DVHs. Dose parameters from the two types of plans (IMRT and VMAT) were compared using a paired t-test. Differences were considered significant if p < 0.05 (2-sided).

**Results**

**Compliance of IMRT and VMAT Plans with NRG-HN002 Dosimetric Compliance Criteria**

Table 4 lists the values for the dosimetric parameters of the target volumes that were obtained using the two treatment planning systems and the two delivery techniques. As can be seen, all dosimetric compliance criteria of the target volumes were met using the two planning techniques, with the exception of the PTV_4800 maximum dose criterion. Coverage requirements (D95% (Gy) and D99% (Gy) for the three PTVs (PTV_6000, PTV_5400 and PTV_4800) were met in all cases. The V60 Gy (%) for CTV_6000, V54 Gy (%) for CTV_5400 and V48 Gy (%) for CTV_4800 were also met. The deviation of the obtained values for PTV_4800 maximum dose over the value defining an acceptable variation (maximum dose of 57.6 Gy within PTV_4800) ranged from 0.4 % to 6.32 % in VMAT plans and from 0.5 % to 5.9 % in IMRT plans. The unacceptable deviation rates (percentage of plans that failed to meet minimum criteria) with respect to this criterion were 40% and 60% amongst the VMAT and IMRT plans, respectively. Figure 2 shows histograms of the maximum doses (D0.03 cc) of Spinal Cord, SpinalCord_05 and BraiStem_03 for all patients. These structures are the only critical structures that are included in the dosimetric compliance criteria. As can...
be seen, these criteria are met for all patients included in the study. The average maximum dose in all plans for SpinalCord_05, Spinal Cord and BrainStem_03 were 45 ± 4 Gy, 40 ± 5 Gy and 30 ± 9 Gy. Figure 3 shows dose histograms for the contralateral parotid, larynx, pharynx and oral cavity and Figure 4 shows dose histograms of esophagus, mandible and Non PTV for all patients. These dosimetric parameters (Figures 3 & 4) are used as guidance for planning and are not scored upon final review of the treatment plans. As can be seen, all recommended dose values were also achieved with some deviations in very few occasions. Both treatment planning systems and treatment techniques gave comparable estimates of the dose levels of critical structures. However, differences were observed occasionally.

Table 4: Values of dosimetric parameters of the target volumes that are included in the dosimetric compliance criteria of NRG HN002 clinical trial.

| Structure   | Dosimetric parameter | VMAT Variance Eclipse | VMAT Philips Pinnacle | IMRT Variance Eclipse | IMRT Philips Pinnacle |
|-------------|-----------------------|------------------------|-----------------------|-----------------------|-----------------------|
| PTV_6000    | D95% (Gy)             | 60.02 ± 0.08           | 60.05 ± 0.04          | 60.0 ± 0.00           | 60.03 ± 0.03          |
|             | D99% (Gy)             | 58.43 ± 0.49           | 59.30 ± 0.10          | 57.00 ± 3.00          | 59.18 ± 0.11          |
|             | Dmax (Gy)              | 65.64 ± 0.18           | 64.17 ± 0.53          | 66.00 ± 1.00          | 64.48 ± 0.62          |
| CTV_6000    | V 60Gy (%)            | 99.46 ± 0.44           | 99.98 ± 0.05          | 98.00 ± 2.00          | 99.80 ± 0.23          |
| PTV_5400    | D95% (Gy)             | 54.05 ± 0.17           | 54.91 ± 0.49          | 55.00 ± 1.00          | 54.99 ± 0.56          |
|             | D99% (Gy)             | 52.77 ± 0.72           | 54.08 ± 0.45          | 53.00 ± 2.00          | 54.05 ± 0.50          |
| CTV_5400    | V 54Gy (%)            | 99.94 ± 0.15           | 99.9 ± 0.12           | 99.70 ± 0.42          | 99.94 ± 0.09          |
| PTV_4800    | D95% (Gy)             | 48.18 ± 0.79           | 48.52 ± 0.59          | 49.44 ± 0.94          | 48.79 ± 0.22          |
|             | D99% (Gy)             | 47.72 ± 0.67           | 48.24 ± 0.12          | 47.00 ± 1.00          | 47.98 ± 0.42          |
|             | Dmax (Gy)              | 57.00 ± 3.00           | 57.00 ± 6.00          | 58.00 ± 3.00          | 62.00 ± 2.00          |
| CTV_4800    | V 48Gy (%)            | 99.67 ± 0.31           | 99.94 ± 0.06          | 99.87 ± 0.11          | 99.86 ± 0.21          |

Figure 2: Histograms of maximum dose of spinal cord_05, spinal cord and brain stem_03 for all patients. E: Eclipse TPS; P: Pinnacle TPS
Figure 3: Dose histograms for the contralateral Parotid, larynx, pharynx and oral cavity for all patients. E: Eclipse TPS; P: Pinnacle TPS

Figure 4: Dose histograms of esophagus, mandible and NonPTV for all patients. E: Eclipse TPS; P: Pinnacle TPS
Discussion

The current study was conducted during the development of the NRG HN002 trial to assess the feasibility of the dosimetric compliance criteria of this clinical trial. Two major treatment techniques (IMRT and VMAT) and treatment planning systems were employed on a limited number of test patients deemed to be representative of those expected to enroll on the trial. The results of this study indicated that all dosimetric compliance criteria could be met with the exception of the maximum dose of PTV_{4800} when it overlapped with PTV_{6000}. An unacceptable deviation rate of less than 10% may be tolerated but a higher rate indicates a consistent problem; therefore, the PTV_{4800} maximum dose criterion was removed from the protocol. The major objective of investigating whether the dosimetric criteria of this clinical trial were achievable, in advance of its activation, was successful. No further dosimetric amendments have been required to the protocol since activation.

As our major goal during this process was to establish feasibility of the radiotherapy quality measures to be used in NRG HN002, we did not aim to conduct a formal comparison of VMAT with IMRT or Pinnacle with Eclipse plans. These two treatment delivery techniques and these two TPS were selected because they were deemed to be the most likely to be used by the various institutions participating in this national clinical trial. However, there were some variations in the results among the two delivery techniques and two TPS. In general, these variations were not statistically significant.

Other comparative treatment planning studies have yielded a similar conclusion of limited differences in results among systems. For instance, Holt et al. [8] compared IMRT and VMAT plans generated by five institutions for five oropharyngeal patients using Pinnacle or Oncentra Master Plan. They used a prescription dose of 56 Gy to the elective PTV and Simultaneous Integrated Boost (SIB) to achieve a prescription PTV dose of 69.12 Gy. They reported a spinal cord maximum dose of 45.1 and 46.6 for VMAT and IMRT, respectively (compared to 40.1 ± 5 Gy, and 40.9 Gy in our study). They also reported, for VMAT and IMRT, respectively: a contralateral parotid mean dose of 22 Gy and 23 Gy (19.5 Gy and 20.1 Gy in our study); a submandibular mean dose of 53 Gy and 54.2 Gy (31.3 Gy and 37.3 Gy in our study); an oral cavity mean dose of 36.7 Gy and 39.4 Gy (28.1 and 26.6 Gy, in our study); and a larynx mean dose of 45.5 Gy and 46.5 Gy (37.5 Gy and 37.0 Gy in our study). It should be noted that the prescription dose for our plans was 60 Gy and in the plans by Holt et al. the prescription dose was 69.12 Gy.

Clemente et al. [9] compared IMRT, VMAT, and helical tomotherapy for oropharyngeal cancer using SIB. They used three prescription dose levels in their study: 70, 63 and 58.1 Gy to regions of macroscopic, microscopic high risk and microscopic low risk. They reported a spinal cord D_{0.1cc} dose of 35.8 Gy and 35.9 Gy for VMAT and IMRT, respectively (compared with a spinal cord maximum dose to D_{0.3cc} of 40.1 Gy and 40.9 Gy in our study). They also reported a D_{0.1cc} dose for the spinal cord PRV (Cord + 4 mm) of 39.4 Gy for both VMAT and IMRT (compared to a maximum dose to D_{0.3 cc} for spinal cord + 5 mm of 43.9 Gy and 40.9 Gy in our study).

Dai et al. [10] compared VMAT and IMRT plans for oropharyngeal carcinoma; their study included fifteen patients and they used two dose level prescription for PTVs (70 Gy and 56 Gy). For VMAT, they used both single arc (arc1) and double arc (arc2 plans). They reported a D_{0.1cc} of the spinal cord of 41.1 Gy, 44.3 Gy and 40.0 Gy for IMRT, arc1 VMAT and arc2 VMAT plans (D_{0.3cc} was 40.9 Gy and 40.1 Gy for IMRT and arc2 VMAT in our study). In summary, taking into account slight differences in the evaluation criteria, our results are consistent within the reported values from other comparative planning studies and similar to these other studies; affirm the reasonableness of feasibility testing for multiple dose criteria across different systems.

Conclusions

All dosimetric compliance criteria for the newly developed head and neck NRG HN002 clinical trial were readily achieved using different treatment planning systems and techniques, with the exception of the PTV_{4800} maximum dose. As a result of this study, the PTV_{4800} maximum dose limit was removed from the dosimetric compliance criteria of the protocol. Both treatment planning systems (Eclipse and Pinnacle) gave similar plans in general. VMAT and IMRT plans using both Eclipse and Pinnacle TPS gave comparable results for the various dose parameters (within the uncertainty levels) of the OARs. This feasibility study, conducted in advance of trial activation, represents a practical improvement in trial planning processes. By establishing in advance that specified dosimetric criteria are feasible across a variety of common treatment planning techniques, the efficiency of a clinical trial launch and the consistency of collected data may be enhanced. In addition, based on the feasibility study, technical guidance can be provided to centers prior to trial launch.

Acknowledgement

This project was supported by grants U10CA180868, U10CA180822 and U24CA180803 and U24 RFA-CA-12-014 from the National Cancer Institute (NCI) and the Cure Grant from the Department of Health in Pennsylvania.

References

1. Sue Yom S, Jimmy Cauldell J, John Waldron, Maura Gillison, Michael Gibson Ping Xia, et al. (2014) NRG-HN002: A Randomized Phase II Trial For Patients With p16 Positive, Non-Smoking Associated, Locally Advanced Oropharyngeal Cancer. Nrg Oncol Clin, p. 1-4.

2. Wheeler R H (2010) Radiation Therapy Oncology Group Rtog 0129 A Phase IIII Trial Of Concurrent Radiation And Chemotherapy (Followed By Surgery For Residual Primary / N2-3 Nodal Disease) For Advanced Head And Neck Carcinomas. Radiation Therapy Oncology Group, USA.

3. Axelrod R, Ang K, Rosenthal M (2009) Rtog 0522 A Randomized Phase IIII Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation , Cisplatin , and Cetuximab [ C225 ] J Followed By Surgery for Selected Patients ] For Stage IIi and IV Head and Neck Carcinomas. Nrg Oncology, USA.

4. Giaddui T, Chen W, Yu J, Lin L, Simone CB, et al. (2016) Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiotherapy for inoperable stage II-IIIB NSCLC. Radiat Oncol 11(66).

Citation: Giaddui T, Yu J, Doemer A, Matuszek M, Nunez F, et al. (2016) A feasibility Study of the Dosimetric Compliance Criteria of the NRG-HN002 Head and Neck Clinical Trial Across Different Radiotherapy Treatment Planning Systems and Delivery Techniques: A Model for Optimizing Initial Trial Launch. J Cancer Prev Curr Res 5(5): 00179. DOI: 10.15406/jcpcr.2016.05.00179

©2016 Giaddui et al.
5. A Li, T Giaddui, W Chen, Y Cui, S McNulty, et al. (2013) An Analysis of Rapid Review Cases That Failed to Meet the RTOG 1005 Contouring and Dose-Volume Criteria. Int J Radiat Oncol 87(2): S228.

6. Pinnacle^ release document 9.10 (2014) Radiation Oncology.

7. MIM Vista, Version 6.5. MIM Software INC, Cleveland, OH, 2015.

8. Holt A1, Van Gestel D, Arends MP, Korevaar EW, Schuring D, et al. (2013) Multi-institutional comparison of volumetric modulated arc therapy vs. intensity-modulated radiation therapy for head-and-neck cancer: a planning study. Radiat Oncol 8(26).

9. Clemente S, Wu B, Sanguineti G, Fusco V, Ricchetti F S, et al. (2011) Smart Arc-based volumetric modulated arc therapy for oropharyngeal cancer: A dosimetric comparison with both intensity-modulated radiation therapy and helical tomotherapy. Int J Radiat Oncol Biol Phys 80(4): 1248-1255.

10. Dai X, Zhao Y, Liang Z, Dassarath M, Wang L, et al. (2015) Volumetric-modulated arc therapy for oropharyngeal carcinoma: a dosimetric and delivery efficiency comparison with static-field IMRT. Phys Med 31(1): 54-59.